Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan
Clicks: 120
ID: 273436
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
120 views
19 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #2 of 2 articles by views in European Heart Journal Supplements
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. Pathological interplay between the heart and kidneys—also known as cardio-renal syndrome (CRS)—is frequently encountered in heart failure and is linke
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (23 words).
Try re-searching for a better abstract.
| Reference Key |
francesco2017europeanpharmacological
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Fedele, Francesco;Karason, Kristjan;Matskeplishvili, Simon; |
| Journal | European Heart Journal Supplements |
| Year | 2017 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.